Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0006 156
mi
from
Orangeburg, SC
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0006 156
mi
from
Orangeburg, SC
Click here to add this to my saved trials
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0006 158
mi
from
Manitowoc, WI
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0006 158
mi
from
Manitowoc, WI
Click here to add this to my saved trials
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0006 114
mi
from
Brooklyn, NY
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0006 114
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0006 160
mi
from
New Haven, CT
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0006 160
mi
from
New Haven, CT
Click here to add this to my saved trials
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0006 117
mi
from
Daytona Beach, FL
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0006 117
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0006 116
mi
from
DeBary, FL
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0006 116
mi
from
DeBary, FL
Click here to add this to my saved trials
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0006 103
mi
from
Saint Louis, MO
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0006 103
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0005 2323
mi
from
Oklahoma City, OK
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0005 2323
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0006 129
mi
from
Wyomissing, PA
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0006 129
mi
from
Wyomissing, PA
Click here to add this to my saved trials
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0006 208
mi
from
Camperdown,
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0006 208
mi
from
Camperdown,
Click here to add this to my saved trials
Pain Coping Skills Training for African Americans With Osteoarthritis
Pain Coping Skills Training for African Americans With Osteoarthritis
Status: Enrolling
Updated:  12/31/1969
UNC Thurston Arthritis Research Center
mi
from
Chapel Hill, NC
Pain Coping Skills Training for African Americans With Osteoarthritis
Pain Coping Skills Training for African Americans With Osteoarthritis
Status: Enrolling
Updated: 12/31/1969
UNC Thurston Arthritis Research Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
FORCE-TJR: Improving Orthopedic Outcomes Through a National TJR Registry
Improving Orthopedic Outcomes Through a National TJR Registry
Status: Enrolling
Updated:  12/31/1969
University of Massachusetts Memorial Health Center; Arthritis and Total Joint Center
mi
from
Worcester, MA
FORCE-TJR: Improving Orthopedic Outcomes Through a National TJR Registry
Improving Orthopedic Outcomes Through a National TJR Registry
Status: Enrolling
Updated: 12/31/1969
University of Massachusetts Memorial Health Center; Arthritis and Total Joint Center
mi
from
Worcester, MA
Click here to add this to my saved trials
Bilateral Total Knee Arthroplasty vs Unicompartment Arthroplasty Retrospective and Clinical Outcome Study
A Retrospective Consecutive Series Patient Preference and Clinical Outcomes Study in Bilateral Knee Osteoarthritis Patients With Both Total Knee Arthroplasty and Unicompartment Knee Arthroplasty Prostheses.
Status: Enrolling
Updated:  12/31/1969
Tri County Orthopeadic Center
mi
from
Leesburg, FL
Bilateral Total Knee Arthroplasty vs Unicompartment Arthroplasty Retrospective and Clinical Outcome Study
A Retrospective Consecutive Series Patient Preference and Clinical Outcomes Study in Bilateral Knee Osteoarthritis Patients With Both Total Knee Arthroplasty and Unicompartment Knee Arthroplasty Prostheses.
Status: Enrolling
Updated: 12/31/1969
Tri County Orthopeadic Center
mi
from
Leesburg, FL
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Arizona Arthritis and Rheumatology Research
mi
from
Glendale, AZ
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Arizona Arthritis and Rheumatology Research
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Arizona Arthritis & Rheumatology Research, PLLC
mi
from
Mesa, AZ
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Arizona Arthritis & Rheumatology Research, PLLC
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Arizona Arthritis Research PLC
mi
from
Phoenix, AZ
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Arizona Arthritis Research PLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
East Bay Rheumatology Medical Group, Inc.
mi
from
San Leandro, CA
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
East Bay Rheumatology Medical Group, Inc.
mi
from
San Leandro, CA
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Arthritis & osteoporosis treatment center,PA
mi
from
Orange Park, FL
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Arthritis & osteoporosis treatment center,PA
mi
from
Orange Park, FL
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Physician's Clinic of Iowa, P.C.
mi
from
Cedar Rapids, IA
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Physician's Clinic of Iowa, P.C.
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Klein & Associates, MD, PA
mi
from
Cumberland, MD
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Klein & Associates, MD, PA
mi
from
Cumberland, MD
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Klein & Associates MD, PA.
mi
from
Hagerstown, MD
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Klein & Associates MD, PA.
mi
from
Hagerstown, MD
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Arthritis, Rheumatic & Back Disease Associates
mi
from
Voorhees, NJ
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Arthritis, Rheumatic & Back Disease Associates
mi
from
Voorhees, NJ
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Robert A. Harrell, III, MD
mi
from
Durham, NC
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Robert A. Harrell, III, MD
mi
from
Durham, NC
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Arthritis Care and Diagnostic Center
mi
from
Dallas, TX
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Arthritis Care and Diagnostic Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Seattle Rheumatology Associates
mi
from
Seattle, WA
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Seattle Rheumatology Associates
mi
from
Seattle, WA
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Arthritis Northwest Rheumatology
mi
from
Spokane, WA
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Arthritis Northwest Rheumatology
mi
from
Spokane, WA
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Florida Medical Clinic
mi
from
Zephyrhills, FL
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Florida Medical Clinic
mi
from
Zephyrhills, FL
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
University of Massachusetts Medical Center
mi
from
Worcester, MA
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
University of Massachusetts Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Pennsylvania Regional Center for Arthritis & Osteoarthritis
mi
from
Wyomissing, PA
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Pennsylvania Regional Center for Arthritis & Osteoarthritis
mi
from
Wyomissing, PA
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Pioneer Research Solutions
mi
from
Cypress, TX
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Pioneer Research Solutions
mi
from
Cypress, TX
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
University of California, Davis - Health Systems
mi
from
Sacramento, CA
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
University of California, Davis - Health Systems
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Glacier View Research Institute
mi
from
Kalispell, MT
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Glacier View Research Institute
mi
from
Kalispell, MT
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Physicians at Brooklyn Heights
mi
from
Brooklyn, NY
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Physicians at Brooklyn Heights
mi
from
Brooklyn, NY
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Kadlec Clinic Rheumatology
mi
from
Kennewick, WA
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Kadlec Clinic Rheumatology
mi
from
Kennewick, WA
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
mi
from
Plovdiv,
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
mi
from
Plovdiv,
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
Stanford University Medical Center
mi
from
Palo Alto, CA
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
Stanford University Medical Center
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
Indiana University School of Medicine
mi
from
Indianapolis, IN
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
Indiana University School of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
Boston Children's Hospital
mi
from
Boston, MA
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
Children's Mercy Hospital
mi
from
Kansas City, MO
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
HackensackUniversity Medical Center
mi
from
Hackensack, NJ
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
HackensackUniversity Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
Children's Hospital at Montefiore
mi
from
Bronx, NY
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
Children's Hospital at Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
Hospital for Special Surgery
mi
from
New York, NY
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
Hospital for Special Surgery
mi
from
New York, NY
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
Duke Children's Hospital and Health Center
mi
from
Durham, NC
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
Duke Children's Hospital and Health Center
mi
from
Durham, NC
Click here to add this to my saved trials